[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624304":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":38,"responsibleParty":56,"collaborators":58,"id":62,"slug":25,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Synbiotic Health","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Bifidobacterium adolescentis iVS-1","EXPERIMENTAL","Probiotic Capsule",[13],"Dietary Supplement: Bifidobacterium adolescentis iVS-1",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo capsule",[19],"Dietary Supplement: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","B. adolescentis iVS-1 (probiotic capsule) delivered orally once daily at a minimum of 8 billion CFU\u002Fday",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo capsule delivered orally once daily",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Shalini Jain, PhD","CONTACT","813-419-0781","jains@musbresearch.com",{"name":36,"role":32,"phone":25,"phoneExt":25,"email":37},"Indushekar Manjunatha","imanjunatha@musbresearch.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"MusB Research LLC","RECRUITING","New Port Richey","Florida","34638","United States",{"type":47,"coordinates":48},"Point",[49,50],-82.71927,28.24418,{"lat":50,"lon":49},[53,54],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":31,"role":55,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[59],{"name":60,"class":61},"MusB Research","UNKNOWN","100624304",false,"NCT07407894","iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults","VITAL-Age Trial (iVS-1 Investigation for Targeting Aging and Longevity)","VITAL","Inclusion Criteria:\n\n* Aged 40-75 years.\n* BMI: 20-34.9 kg\u002Fm².\n* Able and willing to sign informed consent and participate for the study duration.\n\nExclusion Criteria:\n\n* Chronic disease history (liver, kidney, heart).\n* Current pregnancy and\u002For lactating.\n* Colonoscopy and\u002For its preparation within 4 weeks of screening.\n* Those who intend to have children during study period.\n* Current probiotic, prebiotics and\u002For metabolic-altering supplement use.\n* Those who are unable to cooperate with investigators and testing.\n* Known history of cancer and\u002For ongoing cancer treatments.\n* Abuse of drugs, alcohol, tobacco, nicotine and other substances.\n* History of cardiac diseases: atherosclerosis, heart failure, unstable angina, stable angina, etc., and chronic hypoxic disease: emphysema, pulmonary heart disease and others related.\n* History of chronic and major GI disease (pancreatitis, IBS, and IBD) and intestinal surgeries.\n* Type 1 or 2 diabetes mellitus.\n* Poorly controlled chronic diseases (hypertension, hyperlipidemia) that are clinically unstable.\n* Vulnerable groups, including clinically ill, mentally ill, cognitively impaired, minors, and illiterate etc.\n* Significant weight loss (\\>20%) in prior one month.\n* Conditions affecting safety or outcome integrity.",true,"ALL","40 Years","75 Years",{"count":74,"type":75},80,"ESTIMATED","INTERVENTIONAL",[78],"NA","This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.",[81,82],"Healthy Aging","Anti Aging",[84,85,86,87,88,89,90],"Bifidobacterium adolescentis","iVS-1","Aging","Geroscience","Gut Microbiome","Probiotic","Healthspan","2026-04-21",{"date":93,"type":94},"2026-04-22","ACTUAL",{"date":96,"type":94},"2026-02-01",{"date":98,"type":75},"2027-01",{"name":5,"class":6},1]